SCHEMBL17769148

SCHEMBL17769148

Nc1nc(-n2nccn2)c(Cl)nc1C(=O)NCc1cnn2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ BACE1 P56817 2/20 0.44
▸ EPHB3 P54753 4/20 0.43
▸ HSD17B10 Q99714 2/20 0.41
▸ PKM P14618 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ ADORA2A P29274 3/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ GRM5 P41594 2/20 0.39
▸ RIPK2 O43353 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ HDAC1 Q13547 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17768779 0.85 BACE1 (0.42) KDM4EALDH1A1NPC1HTTRAB9A
SCHEMBL17768824 0.83 ADORA2A (0.43) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL17768853 0.81 PRNP (0.49) ALDH1A1SMN1; SMN2MAPK1ADORA2AADORA1
SCHEMBL17768973 0.78 ADORA2A (0.52) SMN1; SMN2ADORA2AADORA1GRM5PIK3CD
SCHEMBL17769154 0.78 HPGD (0.50) KDM4EALDH1A1NPC1HTTSMN1; SMN2
SCHEMBL17768668 0.78 CNR1 (0.49) MAPK1ADORA2AADORA1GRM5EPHX2
SCHEMBL17768661 0.78 ADORA2A (0.42) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL17769005 0.77 ROS1 (0.44) ADORA2AADORA1
SCHEMBL17768814 0.77 ADORA2A (0.52) ADORA2AADORA1GRM5
SCHEMBL17768735 0.76 GRM5 (0.42) ADORA2AADORA1GRM5HDAC1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2018-11-15 — — US claimed
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 — — US disclosed
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2019-11-12 — — US disclosed
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2018-11-15 — — US disclosed
EP-3220910-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES Merck Sharp & Dohme Corp. (US) 2017-09-27 — — EP disclosed
WO-2016081290-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2016-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472347-B2 Aminopyrazine compounds with A2A antagonist properties ADORA2A, ADORA1, ADORA3 KDM4E 3600/4885ALDH1A1 591/4885NPC1 2933/4885
US-20180327385-A1 AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA1, ADORA3 KDM4E 3600/4885ALDH1A1 591/4885NPC1 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback